Dental implants maker receives £4m to expand business

A surgical engineering company which provides full jaw dental implants has raised over £4 million to expand its clinics and explore international growth.

London-based Evo will use the funding to expand capacity at its current facilities and develop new clinics across the UK. The company also hopes to look at expanding into the international market.

Evo uses the latest hi-tech medical manufacturing technology to provide life-changing treatments for patients suffering from severe dental problems caused by advanced gum disease, congenital bone loss or accidents, and who require a full jaw reconstruction.

The clinical team at Evo are able to utilise technologies such as digital scanning, prosthetic manufacturing, 3D printing, and high-precision milling machines to create bespoke jaw dental implants for patients.

Evo has the ability to treat 99% of people who receive a full clinical assessment, even if they have previously been told that their only option is dentures as they don’t have enough bone to anchor conventional dental implants

The funding was provided by investment firm BGF, which has invested around £100 million into healthcare and medical technology companies across the UK.

Evo’s founder and CEO Dr Vijay said: “Evo is taking what’s possible in dentistry today far beyond the limits of what has previously been available. We’ve combined state-of-the-art engineering, innovation and first-class patient care to deliver a solution for the chronic types of tooth problems that inflict millions of people across the UK.

“We chose to partner with BGF because of their culture and approach. We have very ambitious expansion plans and wanted to work with someone who will support us longer-term, and also introduce us to people outside of our immediate space that can help us grow as a business.”

Alistair Brew,BGF, who helped lead the investment said: “Evo is an example of the best of British craftmanship, engineering and technology. The company has built a reputation for clinical excellence and is at the forefront of a nascent, but potentially very large market. Led by Dr Vijay, the team has huge ambitions to take this treatment across the UK and internationally, and we’re delighted to be backing them.”